| 3.39 -0.025 (-0.73%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.63 | 1-year : | 5.11 |
| Resists | First : | 3.96 | Second : | 4.37 |
| Pivot price | 3.58 |
|||
| Supports | First : | 3.3 | Second : | 2.75 |
| MAs | MA(5) : | 3.42 |
MA(20) : | 3.71 |
| MA(100) : | 3.73  |
MA(250) : | 2.94 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 12.2 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 5.17 | Low : | 1.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CCCC ] has closed above bottom band by 22.5%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.48 - 3.5 | 3.5 - 3.52 |
| Low: | 3.34 - 3.36 | 3.36 - 3.38 |
| Close: | 3.36 - 3.39 | 3.39 - 3.42 |
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Sat, 05 Sep 2026
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC) - Seeking Alpha
Thu, 03 Sep 2026
New data detail how a blood-cancer treatment affects immune cells - Stock Titan
Fri, 21 Aug 2026
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Fri, 14 Aug 2026
CCCC (NASDAQ: CCCC) insider plans sale of common stock - Stock Titan
Fri, 14 Aug 2026
Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Fri, 03 Jul 2026
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 123 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 102.7 (%) |
| Shares Short | 34,050 (K) |
| Shares Short P.Month | 23,820 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | -289.5 % |
| Operating Margin | -397.9 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -48.2 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 0.24 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -3.73 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 11.9 |
| Price to Cash Flow | -4.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|